Department of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio, United States of America.
PLoS Pathog. 2022 Jun 16;18(6):e1010588. doi: 10.1371/journal.ppat.1010588. eCollection 2022 Jun.
As intracellular parasites, viruses exploit cellular proteins at every stage of infection. Adenovirus outbreaks are associated with severe acute respiratory illnesses and conjunctivitis, with no specific antiviral therapy available. An adenoviral vaccine based on human adenovirus species D (HAdV-D) is currently in use for COVID-19. Herein, we investigate host interactions of HAdV-D type 37 (HAdV-D37) protein IIIa (pIIIa), identified by affinity purification and mass spectrometry (AP-MS) screens. We demonstrate that viral pIIIa interacts with ubiquitin-specific protease 9x (USP9x) and Ran-binding protein 2 (RANBP2). USP9x binding did not invoke its signature deubiquitination function but rather deregulated pIIIa-RANBP2 interactions. In USP9x-knockout cells, viral genome replication and viral protein expression increased compared to wild type cells, supporting a host-favored mechanism for USP9x. Conversely, RANBP2-knock down reduced pIIIa transport to the nucleus, viral genome replication, and viral protein expression. Also, RANBP2-siRNA pretreated cells appeared to contain fewer mature viral particles. Transmission electron microscopy of USP9x-siRNA pretreated, virus-infected cells revealed larger than typical paracrystalline viral arrays. RANBP2-siRNA pretreatment led to the accumulation of defective assembly products at an early maturation stage. CRM1 nuclear export blockade by leptomycin B led to the retention of pIIIa within cell nuclei and hindered pIIIa-RANBP2 interactions. In-vitro binding analyses indicated that USP9x and RANBP2 bind to C-terminus of pIIIa amino acids 386-563 and 386-510, respectively. Surface plasmon resonance testing showed direct pIIIa interaction with recombinant USP9x and RANBP2 proteins, without competition. Using an alternative and genetically disparate adenovirus type (HAdV-C5), we show that the demonstrated pIIIa interaction is also important for a severe respiratory pathogen. Together, our results suggest that pIIIa hijacks RANBP2 for nuclear import and subsequent virion assembly. USP9x counteracts this interaction and negatively regulates virion synthesis. This analysis extends the scope of known adenovirus-host interactions and has potential implications in designing new antiviral therapeutics.
作为细胞内寄生虫,病毒在感染的各个阶段利用细胞蛋白。腺病毒爆发与严重急性呼吸道疾病和结膜炎有关,但目前尚无特定的抗病毒疗法。一种基于人类腺病毒属 D(HAdV-D)的腺病毒疫苗目前用于 COVID-19。在此,我们通过亲和纯化和质谱(AP-MS)筛选研究了 HAdV-D 型 37(HAdV-D37)蛋白 IIIa(pIIIa)的宿主相互作用。我们证明病毒 pIIIa 与泛素特异性蛋白酶 9x(USP9x)和 Ran 结合蛋白 2(RANBP2)相互作用。USP9x 结合并没有引发其标志性的去泛素化功能,而是使 pIIIa-RANBP2 相互作用失调。在 USP9x 敲除细胞中,与野生型细胞相比,病毒基因组复制和病毒蛋白表达增加,支持 USP9x 的宿主有利机制。相反,RANBP2 敲低会减少 pIIIa 向核内的转运、病毒基因组复制和病毒蛋白表达。此外,用 RANBP2-siRNA 预处理的细胞似乎包含较少的成熟病毒颗粒。用 USP9x-siRNA 预处理、感染病毒的细胞进行透射电子显微镜检查显示,比典型的准晶状病毒排列更大。RANBP2-siRNA 预处理导致在早期成熟阶段积累有缺陷的组装产物。用莱普霉素 B 阻断 CRM1 核输出会导致 pIIIa 保留在细胞核内,并阻碍 pIIIa-RANBP2 相互作用。体外结合分析表明,USP9x 和 RANBP2 分别与 pIIIa 氨基酸 386-563 和 386-510 的 C 末端结合。表面等离子体共振试验显示,pIIIa 与重组 USP9x 和 RANBP2 蛋白直接相互作用,没有竞争。使用另一种遗传上不同的腺病毒类型(HAdV-C5),我们表明所证明的 pIIIa 相互作用对于严重呼吸道病原体也很重要。总之,我们的研究结果表明,pIIIa 劫持 RANBP2 进行核内输入和随后的病毒组装。USP9x 拮抗这种相互作用并负调节病毒合成。该分析扩展了已知腺病毒-宿主相互作用的范围,并可能对设计新的抗病毒治疗方法具有重要意义。